Research, Collaboration and License Agreements - Additional Information (Details)	1 Months Ended					3 Months Ended		12 Months Ended
	Mar. 31, 2022 USD ($) shares	Mar. 31, 2021 USD ($)	Oct. 31, 2020 USD ($)	Aug. 31, 2020 USD ($)	Apr. 30, 2020 USD ($) Product	Mar. 31, 2022 USD ($) shares	Mar. 31, 2021 USD ($)	Dec. 31, 2021 USD ($) shares	Dec. 31, 2020 USD ($)	Oct. 29, 2020 USD ($)	Mar. 31, 2020 shares	Feb. 21, 2020 USD ($)	Nov. 30, 2019 shares
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Common stock, shares issued | shares	38,473,945					38,473,945		38,473,945
Research and development						$ 37,799,000	$ 23,854,000
TSHA-120
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Additional milestone payments						0
Research and development							5,500,000
Upfront payment		$ 5,500,000
Clinical, regulatory and commercial milestones to be received		$ 19,300,000					$ 19,300,000
License Agreement for CLN7
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payment of one-time upfront license fee	$ 300,000
License agreement regulatory related milestones maximum amount payable	7,700,000					7,700,000
License agreement sales-related milestones maximum amount payable	$ 7,500,000					7,500,000
UT Southwestern Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Preclinical activities period under sponsored research agreements					2 years
Minimum licensed product to develop obtain regulatory approval for and commercialize | Product					1
Common stock, shares issued | shares											0		2,179,000
Percentage of fully diluted common stock shares outstanding													20.00%
Percentage of entitled to receive additional shares on fully diluted basis													10.00%
Queens Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Additional milestone payments						0
Queens Agreement | Research and Development Expense
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Cash payment to acquire license agreement					$ 3,000,000.0
Queens Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License agreement regulatory milestones payment												$ 10,000,000.0
License agreement commercial milestones payment												$ 10,000,000.0
Abeona CLN1 Agreements
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License fee payment				$ 3,000,000.0
Purchase of clinical materials and reimbursement incurred development costs			$ 4,000,000.0
Research and development								$ 3,000,000.0	$ 7,000,000.0
Abeona CLN1 Agreements | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License and inventory purchase agreement regulatory related milestones payment				26,000,000.0
License and inventory purchase agreement sales related milestones payment				$ 30,000,000.0
Abeona | Abeona Rett Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Research and development						$ 1,000,000,000.0
Payment of one-time upfront license fee									$ 3,000,000.0
Abeona | Maximum | Abeona Rett Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Regulatory related milestones obligation payable										$ 26,500,000
Sale-related milestones per licensed product and royalties on net sales of licensed products payable										$ 30,000,000.0